These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30489381)

  • 1. Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013.
    Langner I; Haug U; Scholle O; Lindemann C; Schröder C; Riedel O
    J Clin Psychopharmacol; 2019; 39(1):39-45. PubMed ID: 30489381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use and Characteristics of Antipsychotic/Methylphenidate Combination Therapy in Children and Adolescents with a Diagnosis of Attention-Deficit/Hyperactivity Disorder.
    Scholle O; Banaschewski T; Enders D; Garbe E; Riedel O
    J Child Adolesc Psychopharmacol; 2018; 28(6):415-422. PubMed ID: 29768038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.
    Garbe E; Mikolajczyk RT; Banaschewski T; Petermann U; Petermann F; Kraut AA; Langner I
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):452-8. PubMed ID: 23234588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbidities in ADHD children treated with methylphenidate: a database study.
    Kraut AA; Langner I; Lindemann C; Banaschewski T; Petermann U; Petermann F; Mikolajczyk RT; Garbe E
    BMC Psychiatry; 2013 Jan; 13():11. PubMed ID: 23294623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Variability and tendencies in the consumption of methylphenidate in Spain. An estimation of the prevalence of attention deficit hyperactivity disorder].
    Criado Alvarez JJ; Romo Barrientos C
    Rev Neurol; 2003 Nov 1-15; 37(9):806-10. PubMed ID: 14606045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
    Schubert I; Köster I; Lehmkuhl G
    Dtsch Arztebl Int; 2010 Sep; 107(36):615-21. PubMed ID: 20948775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
    Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.
    Liao YT; Yang YH; Kuo TY; Liang HY; Huang KY; Wang TN; Lee Y; McIntyre RS; Chen VC
    Eur Child Adolesc Psychiatry; 2018 Mar; 27(3):279-288. PubMed ID: 28856464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.
    van den Ban E; Souverein PC; Swaab H; van Engeland H; Egberts TC; Heerdink ER
    Atten Defic Hyperact Disord; 2010 Dec; 2(4):213-20. PubMed ID: 21258431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical profile of children with ADHD that require OROS-methylphenidate combined with shorter-acting formulations.
    Zelnik N; Terkel-Dawer R
    Atten Defic Hyperact Disord; 2015 Dec; 7(4):313-8. PubMed ID: 25838111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation.
    Stevens JR; George RA; Fusillo S; Stern TA; Wilens TE
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):49-54. PubMed ID: 20166796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.